Clinical Trial Update: A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years [Phase 2]

View source ↗

Summary

Phase 2 clinical trial to evaluate relapse prevention in multiple sclerosis using mRNA-1195 versus placebo; currently recruiting in adults aged 18 to 55.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• mRNA-1195

Snippet

Sponsor: ModernaTX, Inc. | Conditions: Multiple Sclerosis | Phase 2 | Status: RECRUITING